Seven million times BDNF is a great number, and it did its job: it sold a molecule for more than a decade, outliving the trial that failed, the company that settled, and the papers that were pulled
Similarly, TB-500 has undergone extensive safety evaluation including human research trials showing safety at intravenous doses up to 1,260 mg equivalent, with no dose-limiting toxicities or serious adverse events attributable to the peptide in carefully controlled studies
Notably: BPC-157, KPV, MOTs-C, Emideltide (DSIP), Epitalon, Semax (heptapeptide) and TB-500 are among those expected to be reviewed in July 2026 Other substances, including Cathelicidin LL-37, Dihexa Acetate, PEG-MGF, GHK-Cu and Melanotan II, are under consideration for review by early 2027 Non-injectable GHK-Cu is following a slightly different path, with separate evaluation anticipated before February 2027
The Science of Absorption: Timing and Form Taking the right amount is only half the battle
Free and private
This page does not provide dosing, administration, reconstitution, treatment, or human-use guidance
